<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01374620</url>
  </required_header>
  <id_info>
    <org_study_id>PAL-ANGI2</org_study_id>
    <nct_id>NCT01374620</nct_id>
  </id_info>
  <brief_title>Weekly Paclitaxel and Cyclophosphamide in Metronomic Administration : Dose Escalation Study of Weekly Paclitaxel</brief_title>
  <acronym>PAL-ANGI2</acronym>
  <official_title>Phase I Study : Dose Escalation of Intravenous Weekly Paclitaxel in Association With Metronomic Administration of Cyclophosphamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine the MTD of Paclitaxel in association with metronomic
      Cyclophosphamide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to determine the MTD of Paclitaxel in association with metronomic
      Cyclophosphamide for cancer which present no therapeutic solution
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the iv paclitaxel maximum tolerated dose and recommended dose in association with a fixed dose of oral cyclophosphamide</measure>
    <time_frame>28 days = cycle 1</time_frame>
    <description>A DLT is defined below:
Hematological toxicity:
Polunuclear neutrophils &lt; 500/mm3 for more than 7 days
Febrile neutropenia (Polunuclear neutrophils &lt; 1 000/mm3 and fever &gt; or = 38.5°C) or documented infection
Thrombopenia (Platelets &lt; 25 000/mm3)
Impossibility to administer D8 or D15 due to hematological critera
Non-hematological toxicity:
Any grade 3 or 4 toxicity related to study treatment, with the exception of fatigue and alopecia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of the nature of adverse events</measure>
    <time_frame>During the study treatment, an expected average of 2 months</time_frame>
    <description>According to the NCI-CTCAE scale v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of objective response after 2 cycles</measure>
    <time_frame>After 2 cycles = 2 months</time_frame>
    <description>Objective response (complete response, partial response and stable disease) according to RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of the free-progression median time</measure>
    <time_frame>Until disease progression</time_frame>
    <description>Time between the inclusion and the disease progression (clinical or radiological)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of the Growth Modulation Index (GMI)</measure>
    <time_frame>Until disease progression</time_frame>
    <description>Time to progression on study treatment and time to progression on prior treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the correlation between clinical response and biological parameters</measure>
    <time_frame>Day 1, 8, 15, 21 of cycle 1 and cycle 2</time_frame>
    <description>Biological parameters related to angiogenesis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the severity of adverse events</measure>
    <time_frame>During the study treatment, an expected average of 2 months</time_frame>
    <description>According to the NCI-CTCAE scale v4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Paclitaxel Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A standard dose escalation strategy will be used including 3 to 6 patients at each dose level (Paclitaxel dose escalation + fixed dose of cyclophosphamide)
+ blood collection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort extension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An additional 10 patients will be treated at the recommended dose in order to confirm the recommended paclitaxel dose
+ blood collection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel dose escalation</intervention_name>
    <description>Paclitaxel will be administered intravenously over 60 minutes, at D1, D8 and D15, at a given dose.
The Paclitaxel dose (mg/infusion) levels are as follows:
40
60
70
75
80
85
90</description>
    <arm_group_label>Paclitaxel Dose escalation</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Patients will be treated at the recommended dose in order to confirm the recommended paclitaxel dose in association with metronomic cyclophosphamide</description>
    <arm_group_label>Cohort extension</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>D1 to D28: 50 mg x 2/day/cycle
1 cycle = 28 days</description>
    <arm_group_label>Paclitaxel Dose escalation</arm_group_label>
    <arm_group_label>Cohort extension</arm_group_label>
    <other_name>Endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood collection</intervention_name>
    <description>At D1, D8, D15 and D21 of cycle 1 and cycle 2:2 blood samples for the correlation between clinical response and biological parameters</description>
    <arm_group_label>Paclitaxel Dose escalation</arm_group_label>
    <arm_group_label>Cohort extension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with cancer histologically proved

          -  No other therapeutic proposal after discussion in multidisciplinary consultation

          -  Radiological evidence of the evolving nature of the disease

          -  Measurable disease with at least one measurable lesion according to the criteria
             RECIST 1.1

          -  At least 28 days since prior treatment(systemic treatment or major surgery)

          -  Patient who have recovered from any previous toxicity

          -  Man or woman de ≥ 18 years and ≤ 65 years

          -  Performance Status (ECOG) ≤ 2 within 7 days before inclusion

          -  Polynuclear neutrophils ≥ 1500/mm3, platelets ≥ 100 000/mm3, Hemoglobin ≥ 9 g/dl

          -  Serum Albumin ≥ 36 g/l and lymphocytes ≥ 700/mm3

          -  Total bilirubin and SGPT/ALT and SGOT/AST ≤ 3 ULN(≤ 5 ULN if liver metastases)

          -  Creatinine in normal ranges and Creatinine clairance &gt; 60 ml/min (Cockroft formulae)

          -  Central venous access

          -  Negative pregnancy test for women who may be pregnant within 7 days before inclusion

          -  Effective contraceptive during the treatment period and up to 6 months after the end
             of treatment (for patients of both sexes during their reproductive and child-bearing
             age and their partners)

          -  Patient covered by government health insurance

          -  Informed consent signed by the patient before any specific study procedure

        Exclusion Criteria:

          -  Prior treatment by Paclitaxel

          -  Oral treatment impossible

          -  Known dysphagia, malabsorption or maldigestion

          -  Pre-existing neuropathy clinically symptomatic

          -  Known leptomeningeal brain metastases

          -  Known allergy to Cremophor, to Paclitaxel or one of its excipients (especially
             polyoxyethylene castor oil), to Cyclophosphamide or one of its excipients (lactose,
             sucrose)

          -  Active and uncontrolled infection

          -  Acute urinary tract infection, pre-existing hemorrhagic cystitis

          -  Diabetes insipidus

          -  History or progressive psychiatric illness

          -  Persons under guardianship or detainees

          -  Unable for medical follow-up (geographic, social or mental reasons)

          -  Pregnant, or likely to be or breastfeeding women

          -  Absence of effective contraception for the duration of treatment and 6 months after
             completion of therapy (for patients of both sexes in childbearing or reproductive age
             and their partners)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas PENEL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2011</study_first_submitted>
  <study_first_submitted_qc>June 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2011</study_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

